RPA1 and cancer: Interestingly, all three compounds showed selective cytotoxicity to HCC1937 (Fig 2), indicating the RPA:RAD52 PPI is an effective target for selective killing of BRCA-mutated cancer cell line regardless of the status of synthetic lethality with PARPi.